Penumbra Inc (NYSE:PEN)
$ 186.94 -13.07 (-6.53%) Market Cap: 7.26 Bil Enterprise Value: 7.66 Bil PE Ratio: 549.82 PB Ratio: 6.25 GF Score: 82/100

Penumbra Inc at Canaccord Genuity Growth Conference Transcript

Aug 12, 2020 / 07:30PM GMT
Release Date Price: $237 (+1.76%)
William John Plovanic
Canaccord Genuity Corp., Research Division - Analyst

Great. Thank you. Welcome. With us today -- welcome to the Canaccord Genuity 40th Annual Global Growth Conference. I'm Bill Plovanic. I'm a senior medical device analyst here at Canaccord.

I'm just excited to have Penumbra management with me today. Penumbra is a medical device company. They're focused on the development of novel products to address challenging medical conditions with unmet needs. We believe Penumbra is positioned for continued growth with a portfolio of products that address unmet needs, drive a paradigm change and are in the early stage of market penetration.

With me today is Adam Elsesser. He's CEO and founder of Penumbra. Adam, thanks for joining me today.

Adam Elsesser
Penumbra, Inc. - Co-Founder, Chairman, President & CEO

Yes. Thanks, Bill, for having us. Appreciate it.

Questions & Answers

William John Plovanic
Canaccord Genuity Corp., Research Division - Analyst

No -- so I'd like,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot